A drug discovery company founded by Nobel Prize Laureate Dr. Bob Lefkowitz. Septerna has unlocked G-protein coupled receptors (GPCR) to the full suite of drug discovery tools with their native complex platform.
GPCRs play an integral role in cellular signaling and are of high therapeutic interest. While there are FDA approved drugs that target this class, ~300 GPCRs of high therapeutic interest remain undrugged due to the inability to isolate GPCRs and feed them into modern drug development workflows. This lack of tools reduces the overall probability of success and, best case, produces drugs with adverse side effect profiles in the event discovery efforts are successful. Septerna has overcome these limitations with their native complex platform and is therefore uniquely positioned to develop first-in-class and best-in-class small molecule drugs against indications with high unmet need. With their competitive advantage in screening and pharmacology, Septerna is advancing five pre-clinical programs, each with blockbuster potential.
Headquarters: San Francisco, CA
Investment Date: September 2021
Catalio Investment: Preferred Stock
Catalio LPs Co-Invest: No
Catalio Deal Source: Dr. Bob Lefkowitz
Key Executives: Jeff Finer (CEO)
Technology Source: Duke University
GPCRs play an integral role in cellular signaling and are of high therapeutic interest. While there are FDA approved drugs that target this class, ~300 GPCRs of high therapeutic interest remain undrugged due to the inability to isolate GPCRs and feed them into modern drug development workflows. This lack of tools reduces the overall probability of success and, best case, produces drugs with adverse side effect profiles in the event discovery efforts are successful. Septerna has overcome these limitations with their native complex platform and is therefore uniquely positioned to develop first-in-class and best-in-class small molecule drugs against indications with high unmet need. With their competitive advantage in screening and pharmacology, Septerna is advancing five pre-clinical programs, each with blockbuster potential.
Headquarters: San Francisco, CA
Investment Date: September 2021
Catalio Investment: Preferred Stock
Catalio LPs Co-Invest: No
Catalio Deal Source: Dr. Bob Lefkowitz
Key Executives: Jeff Finer (CEO)
Technology Source: Duke University
Location: United States, California, South San Francisco
Total raised: $290M
Investors 1
| Date | Name | Website |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.07.2023 | Series B | $150M | Logos Capi... |
| 01.02.2022 | Series A | $140M | - |
Mentions in press and media 8
| Date | Title | Description |
| 28.10.2025 | San Francisco is making a comeback. So are these stocks from the City by the Bay | Monday - Friday, 2:00 - 3:00 PM ET San Francisco is on the comeback, which led CNBC to spend a few days to broadcast “Power Lunch” from the network’s stunning studios in the city. Ahead of this special programming, I sought to find the comp... |
| 19.05.2025 | Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly | Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jørgensen is stepping down, as its obesity ... |
| 08.01.2025 | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing By ReutersJanuary 7, 202511:00 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The Nasdaq logo is displayed at the Nasdaq Mark... |
| 17.07.2023 | Septerna Raises $150M in Series B Financing | Septerna, a South San Francisco, CA-based biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), raised $150M in Series B funding. The round was led by RA Capital M... |
| 14.07.2023 | The Week’s 10 Biggest Funding Rounds: Biotech Dominates As Septerna Raises $150M | 12 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2023 with our new curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Tracker. Inve... |
| 11.07.2023 | RA Capital Leads $150M Financing for Septerna and Lead Drug With Oral Edge in Rare Hormone Disease | For a certain hormone deficiency inadequately managed with calcium and vitamin supplements, the only FDA-approved therapy is a daily injection that’s in limited supply and is set to exit the market soon. Septerna Therapeutics is developing ... |
| 31.01.2022 | Septerna Raises $100M in Series A Financing | Septerna, a South San Francisco CA-based biotechnology company, raised $100M in Series A funding. The round was led by Third Rock Ventures with participation from Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital M... |
| - | Septerna | “Making it Real. A New Era of GPCR Drug Discovery Powered by The Native Complex” |